Patents by Inventor Julia Haas

Julia Haas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10441581
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: October 15, 2019
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Publication number: 20190270743
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • Publication number: 20190270749
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
  • Publication number: 20190263811
    Abstract: Provided herein are compound of Formula I-IV and pharmaceutically acceptable salts thereof which exhibit rearranged during transfection (RET) kinase inhibition. In particular, provided herein are novel crystalline forms of 4-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula I), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula II), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-(6-methoxynicotinoyl)-3,6-diazabicyclo[3.1.
    Type: Application
    Filed: October 10, 2018
    Publication date: August 29, 2019
    Inventors: Andrew T. Metcalf, David Fry, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, Julia Haas, Tony P. Tang, Yutong Jiang
  • Publication number: 20190247398
    Abstract: The present application in some embodiments provides a pharmaceutical composition comprising: and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.
    Type: Application
    Filed: October 25, 2018
    Publication date: August 15, 2019
    Inventors: Qian Zhao, Stacey Spencer, Yutong Jiang, Julia Haas, Charles Todd Eary
  • Publication number: 20190218222
    Abstract: Process for preparing (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide (formula I) or a salt thereof by reacting phenyl(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate or a similar derivative (formula 13) with (S)-pyrrolidin-3-ol (formula 14). Process for preparing phenyl(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3,3a-dihydropyrazolo[1,5-a]pyrimidin-3-yl)carbamate (formula 13) or a similar derivative by reduction of (R)-5-(2-(2,5-difluorophenyl) pyrrolidin-1-yl)-3-nitropyrazolo[1,5-a]pyrimidine (formula 11) to (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-amine (formula 12). Process for preparing (R)-2-(2,5-difluorophenyl)pyrrolidine(R)-2-hydroxysuccinate (formula 10) by treating (R)—N—((R)-1-(2,5-difluorophenyl)-3-(1,3-dioxan-2-yl)propyl)-2-methylpropane-2-sulfinamide (formula 19) with an acid and a reducing agent.
    Type: Application
    Filed: May 18, 2017
    Publication date: July 18, 2019
    Inventors: Mark Reynolds, Charles Todd Eary, Stacey Spencer, Derrick Juengst, Bruno Hache, Yutong Jiang, Julia Haas, Steven W. Andrews
  • Patent number: 10351575
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: July 16, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
  • Publication number: 20190211017
    Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
    Type: Application
    Filed: July 25, 2018
    Publication date: July 11, 2019
    Inventors: Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
  • Publication number: 20190183886
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 20, 2019
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Patent number: 10323022
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 18, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven W. Andrews, James F. Blake, Kevin R. Condroski, Julia Haas, Lily Huang, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Jeongbeob Seo
  • Publication number: 20190169193
    Abstract: Methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, Typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of Formula I in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.
    Type: Application
    Filed: July 2, 2018
    Publication date: June 6, 2019
    Inventors: Steven W. Andrews, Julia Haas, Yutong Jiang, Gan Zhang
  • Publication number: 20190151322
    Abstract: Methods for inhibiting a ROS1 kinase with compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein. The compounds and methods provided herein are useful in the treatment of cancer (e.g., ROS1-associated cancers as defined herein).
    Type: Application
    Filed: November 26, 2018
    Publication date: May 23, 2019
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Gabrielle R. Kolakowski
  • Publication number: 20190127373
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Publication number: 20190127375
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Patent number: D858601
    Type: Grant
    Filed: October 29, 2017
    Date of Patent: September 3, 2019
    Assignee: Carl Zeiss AG
    Inventors: Aaron von Fintel, Dominik Meier, Franziska Haas, Alexander Peters, Julia Löffler
  • Patent number: D859494
    Type: Grant
    Filed: October 29, 2017
    Date of Patent: September 10, 2019
    Assignee: Carl Zeiss AG
    Inventors: Aaron von Fintel, Dominik Meier, Franziska Haas, Alexander Peters, Julia Löffler
  • Patent number: D863395
    Type: Grant
    Filed: May 20, 2018
    Date of Patent: October 15, 2019
    Assignee: Carl Zeiss AG
    Inventors: Aaron von Fintel, Dominik Meier, Franziska Haas, Alexander Peters, Julia Löffler
  • Patent number: D863396
    Type: Grant
    Filed: May 20, 2018
    Date of Patent: October 15, 2019
    Assignee: Carl Zeiss AG
    Inventors: Aaron von Fintel, Dominik Meier, Franziska Haas, Alexander Peters, Julia Löffler
  • Patent number: D864273
    Type: Grant
    Filed: October 29, 2017
    Date of Patent: October 22, 2019
    Assignee: Carl Zeiss AG
    Inventors: Aaron von Fintel, Dominik Meier, Franziska Haas, Alexander Peters, Julia Löffler
  • Patent number: D865022
    Type: Grant
    Filed: October 29, 2017
    Date of Patent: October 29, 2019
    Assignee: Carl Zeiss AG
    Inventors: Aaron von Fintel, Dominik Meier, Franziska Haas, Alexander Peters, Julia Löffler